C61
Conditions
Interventions
Group 1: This is a multicenter retrospective observational cohort study. Clinical, laboratory, treatment, and imaging data will be collected from participating centers. Patients will be classified acc
Sponsors
Department of Nuclear Medicine University Hospital Halle (Saale)
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Histologically confirmed prostate adenocarcinoma. Metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. Treatment with at least two cycles of 177Lu-PSMA-617 therapy. Availability of baseline clinical and laboratory data before treatment. At least one follow-up laboratory assessment after treatment. Sufficient clinical documentation for retrospective analysis.
Exclusion criteria
Exclusion criteria: Fewer than two treatment cycles. Missing key baseline or follow-up laboratory data. Follow-up insufficient for hematologic status assessment. Patients receiving concomitant treatments that independently caused severe hematologic toxicity (when identifiable).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| What: Hematologic worsening attributable to disease progression or treatment. When: Evaluated during the first 3–4 treatment cycles and throughout follow-up. How: Data collected retrospectively from electronic medical records, laboratory results, treatment records, and PET/CT images. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dynamic changes of hematologic and biochemical biomarkers Association between cumulative administered activity and hematologic changes Development and validation of dynamic attribution models Identification of disease-driven, treatment-driven, or mixed hematologic worsening | — |
Countries
Germany
Contacts
Public ContactYushuang Hou
Department of Nuclear Medicine University Hospital Halle (Saale)
Outcome results
None listed